Disease · MONDO_0005112

malignant pleural mesothelioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. malignant pleural mesothelioma. Diseases, record MONDO_0005112. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005112

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: malignant pleural mesothelioma; Open Targets
Open Targets ID: MONDO_0005112; Open Targets
Other names: MPM, malignant mesothelioma of pleura, malignant mesothelioma of the pleura, pleura mesothelioma, pleural diffuse malignant mesothelioma, pleural malignant mesothelioma; Open Targets
Disease Ontology: DOID:7474; Disease Ontology
NCI Thesaurus: C7376; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 86 drugs, from ClinicalTrials.gov, FDA and TTD; Open Targets

Drugs86

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Approval	ClinicalTrials.gov	51	51	51	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Approval	ClinicalTrials.gov, FDA and TTD	40	38	38	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov and TTD	11	10	10	Drugs and targets
PEMETREXED DISODIUM	CHEMBL2360464	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
VINORELBINE	CHEMBL553025	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 3	ClinicalTrials.gov and TTD	6	5	5	Drugs and targets

1 to 10 of 86

See all 86 drugs

Targets146

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	8	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/3791	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	8	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/5159	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	7	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	6	Platelet-derived growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/5156	Drugs and targets
TUBA1A	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets

1 to 10 of 146

See all 146 targets

Trials142

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00128102	Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)	Phase 3	661	2020-10-26	Mesothelioma, Lung Cancer	VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02899299	Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients	Phase 3	605	2021-04-14	Mesothelioma	CARBOPLATIN, CISPLATIN, IPILIMUMAB, NIVOLUMAB, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT01907100	Nintedanib (BIBF 1120) in Mesothelioma	Phase 2/3	545	2019-03-18	Mesothelioma	CISPLATIN, NINTEDANIB, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT02784171	Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma	Phase 2/3	520	2024-12-10	Mesothelioma	CISPLATIN, PEMBROLIZUMAB, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT02054806	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)	Phase 1	477	2023-10-30	Solid Tumor	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02709512	Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin	Phase 2/3	249	2023-10-04	Mesothelioma	PEGARGIMINASE	Its record names the disease	ClinicalTrials.gov
NCT02610140	Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)	Phase 2	248	2020-07-17	Mesothelioma	ANETUMAB RAVTANSINE, VINORELBINE	Its record names the disease	ClinicalTrials.gov
NCT04843007	Alvopem® (Pemetrexed) Safety Assessment		199	2024-10-23	Non Small Cell Lung Cancer, Malignant Pleural Mesothelioma	PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT02991482	PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma	Phase 3	144	2022-02-07	Pleural Mesothelioma Malignant Advanced	GEMCITABINE, PEMBROLIZUMAB, VINORELBINE	Its record names the disease	ClinicalTrials.gov
NCT02357147	Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)	Phase 2	124	2020-03-17	Mesothelioma, Malignant	AMATUXIMAB, CISPLATIN, PEMETREXED	Its record names the disease	ClinicalTrials.gov

1 to 10 of 142

See all 142 trials

Comparisons in its trials47

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vorinostat vs Placebo: deaths from any cause	288 of 329	284 of 332	661	NCT00128102	Trial comparisons
Vorinostat vs Placebo: Number of Participants Who Experienced Adverse Events (AEs) Characterized as Grade 3 or Grade 4 According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)	165 of 329	146 of 329	658	NCT00128102	Trial comparisons
Vorinostat vs Placebo: Number of Participants Who Experienced an AE	327 of 329	311 of 329	658	NCT00128102	Trial comparisons
Vorinostat vs Placebo: Number of Participants Who Discontinued Study Treatment Due to an AE	60 of 329	49 of 329	658	NCT00128102	Trial comparisons
Vorinostat vs Placebo: serious adverse events	133 of 329	131 of 329	658	NCT00128102	Trial comparisons
Nivolumab 3mg/kg Plus Ipilimumab 1mg/kg vs Pemetrexed Plus Cisplatin or Carboplatin: deaths from any cause	251 of 303	259 of 302	605	NCT02899299	Trial comparisons
Nivolumab 3mg/kg Plus Ipilimumab 1mg/kg vs Pemetrexed Plus Cisplatin or Carboplatin: serious adverse events	188 of 300	106 of 284	584	NCT02899299	Trial comparisons
First Course Pembrolizumab 10 mg/kg vs Second Course Pembrolizumab 10 mg/kg: deaths from any cause	426 of 477	6 of 11	488	NCT02054806	Trial comparisons
First Course Pembrolizumab 10 mg/kg vs Second Course Pembrolizumab 10 mg/kg: serious adverse events	160 of 475	3 of 11	486	NCT02054806	Trial comparisons
Arm A - Cisplatin/Pemetrexed vs Arm B - Cisplatin/Pemetrexed/Pembrolizumab: Phase III: Objective Response Rate	83 of 218	138 of 222	440	NCT02784171	Trial comparisons

1 to 10 of 47

See all 47 comparisons in its trials

Papers from its trials128

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37931632	RESULT	1	PubMed
36463732	RESULT	1	PubMed
34430349	RESULT	1	PubMed
30962585	RESULT	1	PubMed
30522700	RESULT	1	PubMed
29975406	RESULT	1	PubMed
29559561	RESULT	1	PubMed
29462123	RESULT	1	PubMed
29284010	RESULT	1	PubMed
29116900	RESULT	1	PubMed

1 to 10 of 128

See all 128 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005112

GET https://conductscience.org/api/diseases/v1/MONDO_0005112/drugs?page=2

API reference For AI assistants